跳至主要内容
临床试验/NCT06692972
NCT06692972招募中不适用

Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

China-Japan Friendship Hospital2 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2024年12月25日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
500
试验地点
2
主要终点
Tumor regression rate

研究概览

简要总结

Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.

详细描述

This study intends to retrospectively screen and include participants according to inclusion and exclusion criteria, and collect the clinical data of participants by previous medical records. Imaging tools will be used to quantify changes in the spatial location, diameter and volume of target lesions to evaluate tumor regression rate and radiotherapy efficacy, and to explore tumor regression pattern and establish model. In addition, the relationship between tumor regression rate, incidence of adverse radiation events, prognosis and related factors will be analysed.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years old;
  • Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy;
  • The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy);
  • The target lesion of the lung receiving radiotherapy can be measured;
  • Imaging data can be obtained before and after radiotherapy;
  • Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose.
  • Exclusion Criteria:
  • Before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment;
  • The radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose <50Gy, stereotactic radiotherapy with biologically effective dose <100Gy);
  • Required imaging data cannot be obtained;
  • Other conditions considered by the investigator to be inappropriate for enrollment.

排除标准

  • 未提供

结局指标

主要结局

Tumor regression rate

时间窗: Within 1 year after completion of radiotherapy.

(1- post-treatment tumor volume/baseline tumor volume)×100%

次要结局

  • Objective response rate(Within 1 year after completion of radiotherapy.)
  • Disease control rate(Within 1 year after completion of radiotherapy.)
  • Progression-free survival(From the start of treatment until the time of disease progression or death, assessed up to 120 months.)
  • Overall survival(From the start of treatment until the time of death, assessed up to 120 months.)
  • Adverse event rate(Within 1 year after completion of radiotherapy.)

研究者

发起方
China-Japan Friendship Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Guangying Zhu

Clinical Professor, Chief Physician

China-Japan Friendship Hospital

研究点 (2)

Loading locations...

相似试验

The Regression Pattern of Primary Lesions in Lung... | 临床试验